1. The full health, economic, and social benefits of prospective Strep A vaccination.
- Author
-
Cadarette, Daniel, Ferranna, Maddalena, Cannon, Jeffrey W., Abbas, Kaja, Giannini, Fiona, Zucker, Leo, and Bloom, David E.
- Subjects
VACCINATION ,VACCINE effectiveness ,STREPTOCOCCUS pyogenes ,MEDICAL care costs ,COMMUNICABLE diseases - Abstract
Recent research has documented a wide range of health, economic, and social benefits conferred by vaccination, beyond the direct reductions in morbidity, mortality, and future healthcare costs traditionally captured in economic evaluations. In this paper, we describe the societal benefits that would likely stem from widespread administration of safe and effective vaccines against Streptococcus pyogenes (Strep A), which was estimated to be the fifth-leading cause of infectious disease deaths globally prior to the COVID-19 pandemic. We then estimate the global societal gains from prospective Strep A vaccination through a value-per-statistical-life approach. Estimated aggregate lifetime benefits for 30 global birth cohorts range from $1.7 to $5.1 trillion, depending on the age at which vaccination is administered and other factors. These results suggest that the benefits of Strep A vaccination would be large and justify substantial investment in the vaccines' development, manufacture, and delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF